Published: February 04, 2011
Innocutis Medical Signs Exclusive Marketing Agreement for INSORB Absorbable Skin Stapler
CHARLESTON, S.C. - (BUSINESS WIRE) - Innocutis
Medical, a dermatology company focused on novel surgical devices and
specialty pharmaceuticals, is pleased to announce an exclusive
marketing agreement with Incisive Surgical, Inc. (Plymouth MN)
for the sales and marketing rights within the dermatology market for the
patented INSORB
Absorbable Skin Stapler, a revolutionary new modality for skin
closure. The INSORB Stapler uses bioabsorbable staples that are placed
under the skin and dissolve in the body within a matter of months. The
staples, which are comprised of the same material as the leading
bioabsorbable sutures, break down naturally, meaning there is no need
for post-operative removal. With over a half a million surgical cases
performed within the hospital market, INSORB has developed a solid and
proven track record. INSORB's introduction to the dermatology community
will allow for increased surgical efficiency, improved cosmetic
outcomes, and reduced risk of infection over traditional suture
techniques. Innocutis will introduce INSORB to the dermatology
community February 5th, 2011 at the American Academy of Dermatology in
New Orleans, LA.
"We are pleased to join forces with INNOCUTIS to bring our technology to
this exciting new market for us," said John L. Shannon, Jr., President
and Chief Executive Officer of Incisive Surgical. "We have enjoyed much
success in the surgical arena, including obstetrics & gynecology,
orthopedic, general and plastic surgery, and look forward to offering
the profound benefits of this technology to the dermatology community."
"We believe that our focus on both medical and surgical dermatology sets
us apart as a company that understands the growing needs of the
dermatology specialty," said Chuck Jenkins, Vice President of Sales and
Marketing for Innocutis. "We are committed to being 'best-in-class' in
skin-related therapies and providing clinicians with improved solutions
for managing their daily challenges."
Innocutis believes the INSORB absorbable subcuticular stapler will
greatly enhance the efficiency in dermatologists' offices nationally
while providing a marked advancement in the cosmetic outcome seen by
their patients. The INSORB Device contains 30 sterile staples
comprised of 70% PLA and 30% PGA producing a benign polymer that is not
only strong but also dissolves in 90-120 days. For dermatologists, they
now have the ability to utilize a subcuticular closure modality without
the need for post operative suture removal. INNOCUTIS intends to have
their representatives participate in surgical scenarios with their
doctors to ensure surgical technique is followed and outcomes are
exceptional.
About Innocutis Medical:
Innocutis
Medical, LLC is a privately-held pharmaceutical and surgical device
company specializing in the sales, marketing and development of products
focused on the treatment of dermatological conditions. For more
information please contact us at info@innocutis.com
or call 800-499-4468.
About Incisive Surgical:
Incisive
Surgical, Inc. is a privately-held medical device company
established to develop proprietary mechanical surgical solutions for
skin closure. For more information or to request a media kit, contact info@insorb.com
or visit www.insorb.com.
For Innocutis Medical, LLC
Jon Knowles, 800-499-4468
info@innocutis.com
Copyright © 2012, Business Wire, Inc., All rights reserved.
Copyright © 2012, NewsBlaze,
Daily News
Search News
